Inhibitex, Inc.

Few Clouds At BMS It must have been all smiles at Bristol Myers Squibb Company (BMS) when its second-quarter earnings announcement propelled its stock price up by over 11%, more than double the st

Merck & Co. Inc. 's decision to take a $2.9bn pre-tax intangible asset impairment charge against its 2016 financial results due to a reassessment of the value of Phase II hepatitis C candidate uprifo

It's difficult to raise eyebrows with mid-stage data in genotype 1 patients several years into the hepatitis C combination therapy era, but Johnson & Johnson and Achillion Pharmaceuticals Inc.

There aren't many privately held UK-based pharmaceutical companies that can boast of appointing an inventor behind one of the world's biggest selling drugs to its management team. But Nucana's new CSO